Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type i and type ii interferon signatures

Arthritis and Rheumatology

Volumn 66, Issue 6, 2014, Pages 1583-1595

  Chiche, Laurent ^a,b   Jourde Chiche, Noémie ^a,b,c   Whalen, Elizabeth ^a   Presnell, Scott ^a   Gersuk, Vivian ^a   Dang, Kristen ^a   Anguiano, Esperanza ^c   Quinn, Charlie ^a   Burtey, Stéphane ^b   Berland, Yvon ^b   Kaplanski, Gilles ^b   Harle, Jean Robert ^b   Pascual, Virginia ^c   Chaussabel, Damien ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Baylor Institute for Immunology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIMALARIAL AGENT; BETA INTERFERON; CORTICOSTEROID; DOUBLE STRANDED DNA; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; TRANSCRIPTOME;

ADULT; ADULT DISEASE; AGED; ANALYTIC METHOD; ARTICLE; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MODULAR TRANSCRIPTIONAL REPERTOIRE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; INTERFERON TYPE I; INTERFERON-ALPHA; INTERFERON-BETA; INTERFERON-GAMMA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84901641596     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38628     Document Type: Article

References (52)

1. Gonzalez-Navajas JM, Lee J, David M, Raz E,. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012; 12: 125-35.
2. Ronnblom L, Eloranta ML,. The interferon signature in autoimmune diseases. Curr Opin Rheumatol 2013; 25: 248-53.
3. Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A,. Fifty years of anti-ds DNA antibodies: are we approaching journey's end? Rheumatology (Oxford) 2007; 46: 1052-6.
4. Ahearn JM, Liu CC, Kao AH, Manzi S,. Biomarkers for systemic lupus erythematosus. Transl Res 2012; 159: 326-42.
5. Pascual V, Chaussabel D, Banchereau J,. A genomic approach to human autoimmune diseases. Annu Rev Immunol 2010; 28: 535-71.
6. Chiche L, Jourde-Chiche N, Pascual V, Chaussabel D,. Current perspectives on systems immunology approaches to rheumatic diseases. Arthritis Rheum 2013; 65: 1407-17.
7. Kirou KA, Gkrouzman E,. Anti-interferon α treatment in SLE. Clin Immunol 2013; 148: 303-12.
8. Petri M, Singh S, Tesfasyone H, Dedrick R, Fry K, Lal P, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009; 18: 980-9.
9. Landolt-Marticorena C, Bonventi G, Lubovich A, Ferguson C, Unnithan T, Su J, et al. Lack of association between the interferon-α signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009; 68: 1440-6.
10. Tektonidou MG, Ward MM,. Validity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseases. Arthritis Res Ther 2010; 12: R179.
11. Wong D, Kea B, Pesich R, Higgs BW, Zhu W, Brown P, et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One 2012; 7: e29161.
12. Hall JC, Casciola-Rosen L, Berger AE, Kapsogeorgou EK, Cheadle C, Tzioufas AG, et al. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A 2012; 109: 17609-14.
13. Harigai M, Kawamoto M, Hara M, Kubota T, Kamatani N, Miyasaka N,. Excessive production of IFN-γ in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol 2008; 181: 2211-9.
14. Karonitsch T, Feierl E, Steiner CW, Dalwigk K, Korb A, Binder N, et al. Activation of the interferon-γ signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum 2009; 60: 1463-71.
15. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009; 60: 3098-107.
16. Obermoser G, Presnell S, Domico K, Xu H, Wang Y, Anguiano E, et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 2013; 38: 831-44.
17. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008; 29: 150-64.
18. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
19. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
20. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al, for the OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550-8.
21. Petri M, Buyon J, Kim M,. Classification and definition of major flares in SLE clinical trials. Lupus 1999; 8: 685-91.
22. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973-7.
23. Smyth GK,. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3:article 3.
24. Arasappan D, Tong W, Mummaneni P, Fang H, Amur S,. Meta-analysis of microarray data using a pathway-based approach identifies a 37-gene expression signature for systemic lupus erythematosus in human peripheral blood mononuclear cells. BMC Med 2011; 9: 65.
25. Malhotra S, Bustamante MF, Perez-Miralles F, Rio J, Ruiz de Villa MC, Vegas E, et al. Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis. PLoS One 2011; 6: e23634.
26. Taylor MW, Tsukahara T, McClintick JN, Edenberg HJ, Kwo P,. Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment. J Transl Med 2008; 6: 66.
27. Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res 2013; 41: D1040-6.
28. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, et al. Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-a monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1785-96.
29. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2951-62.
30. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, et al. Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3958-67.
31. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res 2009; 19: 1639-45.
32. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-23.
33. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610-5.
34. Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011; 70: 2029-36.
35. Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA,. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Ann Rheum Dis 2008; 67: 1069-75.
36. Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010; 465: 937-41.
37. Koh GC, Schreiber MF, Bautista R, Maude RR, Dunachie S, Limmathurotsakul D, et al. Host responses to melioidosis and tuberculosis are both dominated by interferon-mediated signaling. PLoS One 2013; 8: e54961.
38. Kropp KA, Robertson KA, Sing G, Rodriguez-Martin S, Blanc M, Lacaze P, et al. Reversible inhibition of murine cytomegalovirus replication by γ interferon (IFN-γ) in primary macrophages involves a primed type I IFN-signaling subnetwork for full establishment of an immediate-early antiviral state. J Virol 2011; 85: 10286-99.
39. Liu SY, Sanchez DJ, Aliyari R, Lu S, Cheng G,. Systematic identification of type I and type II interferon-induced antiviral factors. Proc Natl Acad Sci U S A 2012; 109: 4239-44.
40. Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, et al, on behalf of the BLISS-52 and BLISS-76 Study Groups. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013; 65: 2143-53.
41. Gough DJ, Messina NL, Hii L, Gould JA, Sabapathy K, Robertson AP, et al. Functional crosstalk between type I and II interferon through the regulated expression of STAT1. PLoS Biol 2010; 8: e1000361.
42. Negishi H, Osawa T, Ogami K, Ouyang X, Sakaguchi S, Koshiba R, et al. A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc Natl Acad Sci U S A 2008; 105: 20446-51.
43. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 2002; 99: 15669-74.
44. Peng SL, Moslehi J, Craft J,. Roles of interferon-γ and interleukin-4 in murine lupus. J Clin Invest 1997; 99: 1936-46.
45. Haas C, Ryffel B, Le Hir M,. IFN-γ receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB×NZW)F1 mice. J Immunol 1998; 160: 3713-8.
46. Crow MK,. Type I interferon and autoimmune disease. Autoimmunity 2003; 36: 445-6.
47. Crow MK, Kirou KA, Wohlgemuth J,. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003; 36: 481-90.
48. Bissonnette R, Papp K, Maari C, Yao Y, Robbie G, White WI, et al. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-α monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol 2010; 62: 427-36.
49. Kalunian K, Merrill JT, Maciuca R, Ouyang WJ, McBride JM, Townsend MJ, et al. Efficacy and safety of rontalizumab (anti-interferon α) in SLE subjects with restricted immunosuppressant use: results of a randomized, double-blind, placebo-controlled phase 2 study [abstract]. Arthritis Rheum 2012; 64 Suppl: S1111.
50. Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, et al. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013; 65: 1011-21.
51. Lyons PA, McKinney EF, Rayner TF, Hatton A, Woffendin HB, Koukoulaki M, et al. Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis. Ann Rheum Dis 2010; 69: 1208-13.
52. Bloom CI, Graham CM, Berry MP, Rozakeas F, Redford PS, Wang Y, et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One 2013; 8: e70630.